C4 Therapeutics, Inc. 8-K

What Happened
C4 Therapeutics, Inc. announced on April 9, 2026 that its Board approved an amendment to the company's by‑laws, effective immediately, to designate exclusive federal forums for certain securities-law claims. The amendment specifies the U.S. District Court for the District of Massachusetts and the U.S. District Court for the District of Delaware as the sole venues for any complaint asserting a cause of action arising under the Securities Act of 1933 or the Securities Exchange Act of 1934, unless the company gives written consent to a different forum. The company filed the text of the by‑laws amendment as Exhibit 3.1 to its Form 8‑K.

Key Details

• Board approval date: April 9, 2026; amendment effective immediately.
• Designated exclusive forums: U.S. District Court for the District of Massachusetts and U.S. District Court for the District of Delaware.
• Scope: Applies to complaints asserting causes of action under the Securities Act of 1933 and the Securities Exchange Act of 1934 (and related rules/regulations), unless the company consents in writing to another forum.
• Filing: Amendment No. 1 to Second Amended and Restated By‑laws is filed as Exhibit 3.1 to the 8‑K.

Why It Matters
This by‑laws change determines where federal securities claims against C4 Therapeutics must be brought, which affects procedural aspects of litigation such as venue and potentially timing and legal strategy. For investors, the amendment clarifies the company’s chosen federal courts for Securities Act and Exchange Act disputes—information that may be relevant if any securities‑related litigation arises.